Canada's Generics Export Program Falters Amid Litigation Fears

Law360, New York (November 26, 2004, 12:00 AM EST) -- Canadian generic drug makers are opting out of the country’s trailblazing efforts to supply developing countries with patented drugs, blaming excessive safeguards for patent holders under the new law, according to a published report.

Drug makers are choosing not to participate in the government's generic export scheme due to the lack of financial incentives, Jeff Connell of the Canadian Generic Pharmaceutical Association (CGPA) told the Inter Press Service.

In May, Canada passed the Jean Chrétien Pledge to Africa Act, named after the country’s former Prime Minister,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.